Eperezolid

Overview

Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit . Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of chloramphenicol ( HY-B0239 ) and lincomycin ( HY-117660 )) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC 90 for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant ( HY-121544 ) Staphylococci and vancomycin-resistant ( HY-B0671 ) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Bacterial Infection | Products > Disease Areas > Mycobacterium Tuberculosis Infection | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > Antibiotic

Product Information

• Catalog No.: HY-10393
• CAS No.: 165800-04-4
• Molecular Formula: C18H23FN4O5
• Molecular Weight: 394.40
• Purity: 96.55%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution
• Availability: In-stock

Source

Original product source